Ascentage Pharma’s Bcl-2 selective inhibitor lisaftoclax (APG-2575) has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL). It is approved in patients who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The decision makes lisaftoclax the […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!